Cargando…

Cytoreductive treatment patterns among US veterans with polycythemia vera

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thrombotic and cardiovascular risk, which are key contributors to patient morbidity and mortality. The Veterans Health Administration (VHA) is the largest integrative health network in the United States. Av...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parasuraman, Shreekant, Yu, Jingbo, Paranagama, Dilan, Shrestha, Sulena, Wang, Li, Baser, Onur, Scherber, Robyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935975/ https://www.ncbi.nlm.nih.gov/pubmed/29728092 http://dx.doi.org/10.1186/s12885-018-4422-6

Ejemplares similares

Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data
por: Parasuraman, Shreekant, et al.
Publicado: (2019)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Trends in overall mortality among US veterans with primary myelofibrosis
por: Tashi, Tsewang, et al.
Publicado: (2023)

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Grunwald, Michael R., et al.
Publicado: (2018)

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
por: Mesa, Ruben, et al.
Publicado: (2018)

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2020)

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
por: Grunwald, Michael R., et al.
Publicado: (2019)

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey
por: Yu, Jingbo, et al.
Publicado: (2020)

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study
por: Zwicker, Jeffrey I., et al.
Publicado: (2021)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review
por: Parasuraman, Shreekant, et al.
Publicado: (2016)

PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?
por: Yokus, Osman, et al.
Publicado: (2023)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
por: Yu, Jingbo, et al.
Publicado: (2018)

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
por: Crodel, Carl C., et al.
Publicado: (2021)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Management of polycythemia vera: A survey of treatment patterns in Italy
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2022)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Bilateral adrenal hemorrhage in polycythemia vera
por: Bhandari, Shruti, et al.
Publicado: (2016)

Therapy of polycythemia vera: is it time to change?
por: Passamonti, Francesco, et al.
Publicado: (2017)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

When hemolysis masks polycythemia vera
por: Derrieux, Coralie, et al.
Publicado: (2019)

Takotsubo Cardiomyopathy Associated with Polycythemia Vera
por: Basnet, Sijan, et al.
Publicado: (2018)

Is there a gender effect in polycythemia vera?
por: Palandri, Francesca, et al.
Publicado: (2020)

Polycythemia Vera Presenting as Hemorrhagic Stroke
por: Balagopal, Krishnan, et al.
Publicado: (2021)

Volumetric Splenomegaly in Patients With Polycythemia Vera
por: Lee, Myung-Won, et al.
Publicado: (2022)

Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
por: Marchioli, Roberto, et al.
Publicado: (2011)

Idiopathic thrombocytopenic purpura coexisting with polycythemia vera
por: Niscola, Pasquale, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oi8b3nma8o0p5kkv57vs5qttjj